X4 Pharmaceuticals (XFOR) Tops Q4 EPS by 56c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of $0.29, $0.56 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• MoffettNathanson cuts Chewy to neutral as growth slows, target slashed
• J.M. Smucker (SJM) PT Raised to $130 at UBS as 'Risk/Reward Skews to the Upside'